LNC secure 6,5 million euros funding for microbiota-focused strategy – looking to IPO
Oct 2, 2017
LNC Therapeutics has raised €6.5m in a Series C funding round as the company announces a new chief science officer and steps up an ‘ambitious’ microbiota-orientated strategy that it hopes will drive an IPO by the end of 2019.
In the same category
Press / Medias
Bordeaux : un traitement prometteur contre l’obésité développé à base d’une...